Targeting p53-Driven FOXM1 Suppresses Tumor Growth and Synergistically Sensitizes to Chemotherapy in Triple-Negative Breast Cancer Models.

Sayra Dilmac, Nermin Kahraman, Ferah Comert Onder, Ogun Ali Gul, Bulent Ozpolat

Abstract read

In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sayra DilmacDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Nermin KahramanDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Ferah Comert OnderDepartment of Medical Biology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale 17100, Türkiye.ORCID 0000-0002-4037-1979

Ogun Ali GulDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Bulent OzpolatDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen, progesterone, and HER2 receptors; an aggressive phenotype; high rates of early relapse and metastasis; and the worst mortality rates among all breast cancer subtypes. Currently, there is no effective curative targeted therapy for TNBC and chemotherapy remains the primary treatment for TNBC. Therefore, there is a critical need to develop highly effective, novel therapies to improve patient survival. We previously validated FOXM1, a proto-oncogenic transcription factor, for the first time as a potential molecular target in TNBC through genetic knockdown studies in mice. We show that FOXM1 expression is associated with shorter patient survival and is a marker of poor prognosis. There is no FDA-approved FOXM1 inhibitor. We found that patients with

Indexed as

Antineoplastic AgentsForkhead Box Protein M1Triple Negative Breast NeoplasmsTumor Suppressor Protein p53AnimalsApoptosisCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeXenograft Model Antitumor AssaysAntineoplastic AgentsForkhead Box Protein M1FOXM1 protein, humanTumor Suppressor Protein p53FOXM1FOXM1 inhibitorsmall molecule inhibitorTNBC

Identifiers

PMID42505347

DOI10.3390/cells15141237

PMCPMC13406395

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.